Outcomes in patients with classic Hodgkin lymphoma refractory or intolerant to brentuximab vedotin and anti-PD-1 therapy: a real world analysis from 15 U.S. academic centers
Guardado en:
| Udgivet i: | Blood Cancer Journal vol. 15, no. 1 (Dec 2025), p. 45 |
|---|---|
| Udgivet: |
Springer Nature B.V.
|
| Fag: | |
| Online adgang: | Citation/Abstract Full Text - PDF |
| Tags: |
Ingen Tags, Vær først til at tagge denne postø!
|